These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1150 related items for PubMed ID: 16280763

  • 1. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G, Perdonà S, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R.
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
    Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F.
    J Clin Oncol; 2005 Feb 01; 23(4):808-15. PubMed ID: 15681525
    [Abstract] [Full Text] [Related]

  • 3. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S.
    Eur Urol; 2007 Jul 01; 52(1):106-14. PubMed ID: 17270340
    [Abstract] [Full Text] [Related]

  • 4. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F, Rubagotti A, Conti G, Potenzoni D, Manganelli A, Del Monaco D.
    Cancer Chemother Pharmacol; 2005 Oct 01; 56(4):415-20. PubMed ID: 15838655
    [Abstract] [Full Text] [Related]

  • 5. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
    Saltzstein D, Sieber P, Morris T, Gallo J.
    Prostate Cancer Prostatic Dis; 2005 Oct 01; 8(1):75-83. PubMed ID: 15685254
    [Abstract] [Full Text] [Related]

  • 6. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.
    Bedognetti D, Rubagotti A, Conti G, Francesca F, De Cobelli O, Canclini L, Gallucci M, Aragona F, Di Tonno P, Cortellini P, Martorana G, Lapini A, Boccardo F.
    Eur Urol; 2010 Feb 01; 57(2):238-45. PubMed ID: 19481335
    [Abstract] [Full Text] [Related]

  • 7. Treatment of bicalutamide-induced breast events.
    Sieber PR.
    Expert Rev Anticancer Ther; 2007 Dec 01; 7(12):1773-9. PubMed ID: 18062751
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.
    Perdonà S, Autorino R, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Bianco AR, Di Lorenzo G.
    Lancet Oncol; 2005 May 01; 6(5):295-300. PubMed ID: 15863377
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
    Serretta V, Altieri V, Morgia G, Nicolosi F, De Grande G, Mazza R, Melloni D, Allegro R, Ferraù F, Gebbia V.
    Clin Genitourin Cancer; 2012 Sep 01; 10(3):174-9. PubMed ID: 22502790
    [Abstract] [Full Text] [Related]

  • 10. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
    McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J.
    J Urol; 2006 Jul 01; 176(1):75-80. PubMed ID: 16753373
    [Abstract] [Full Text] [Related]

  • 11. Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain?
    Ozen H, Akyol F, Toktas G, Eskicorapci S, Unluer E, Kuyumcuoglu U, Abay E, Cureklibatur I, Sengoz M, Yalcin V, Akpinar H, Zorlu F, Sengor F, Karaman I.
    J Urol; 2010 Aug 01; 184(2):519-24. PubMed ID: 20620411
    [Abstract] [Full Text] [Related]

  • 12. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Van Poppel H.
    Eur Urol; 2007 Jul 01; 52(1):115. PubMed ID: 17270341
    [No Abstract] [Full Text] [Related]

  • 13. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT.
    Urology; 1995 Dec 01; 46(6):849-55. PubMed ID: 7502428
    [Abstract] [Full Text] [Related]

  • 14. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I.
    J Urol; 2000 Nov 01; 164(5):1579-82. PubMed ID: 11025708
    [Abstract] [Full Text] [Related]

  • 15. The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain.
    Nuttall MC, Harris JP, Dawkins GP.
    BJU Int; 2007 Feb 01; 99(2):243-4. PubMed ID: 17313420
    [No Abstract] [Full Text] [Related]

  • 16. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.
    Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K.
    Int J Radiat Oncol Biol Phys; 2004 Oct 01; 60(2):476-83. PubMed ID: 15380582
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group.
    BJU Int; 2006 Feb 01; 97(2):247-54. PubMed ID: 16430622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.